[Hyperkalemia treatment in chronic kidney disease patients: overview on new K binders and possible therapeutic approaches]

Area of Science:

• Nephrology
• Internal Medicine
• Pharmacology

Background:

• Hyperkalaemia is a frequent complication in non-dialysis Chronic Kidney Disease (CKD) patients.
• Elevated potassium levels are linked to weakness, arrhythmias, mortality, and CKD progression.
• Refractory hyperkalaemia often necessitates renal replacement therapy and can lead to discontinuation of crucial renin-angiotensin-system inhibitors.

Purpose of the Study:

• To review the current landscape of hyperkalaemia management in CKD.
• To evaluate the efficacy and safety of novel potassium-binding resins compared to traditional agents.
• To highlight the therapeutic potential of patiromer and ZS-9 in CKD patients.

Main Methods:

• Literature review of studies on hyperkalaemia treatments in Chronic Kidney Disease.
• Comparative analysis of efficacy and adverse effect profiles of sodium/calcium-polystyrenesulfonate (SPS), patiromer, and ZS-9.
• Assessment of specific advantages of newer agents for CKD patient populations.

Main Results:

• Traditional resins like SPS have shown limited efficacy and significant adverse effects.
• Patiromer and ZS-9 demonstrate high efficacy in reducing serum potassium levels.
• These novel resins exhibit a more favorable safety profile compared to polystyrenesulfonates.
• Patiromer offers a sodium-free option, beneficial for fluid-restricted CKD patients.
• ZS-9 provides rapid potassium reduction, suitable for acute hyperkalaemia management.

Conclusions:

• Novel potassium binders, patiromer and ZS-9, represent significant advancements in managing hyperkalaemia in CKD.
• These agents offer improved efficacy and safety over traditional treatments.
• Their distinct properties allow for tailored therapeutic strategies in various CKD scenarios, including acute and chronic management.